Brian A. Jonas

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Daniel A. Pollyea

UNITED STATES

View details

Jan Novak

CZECH REPUBLIC

View details

Yishai Ofran

ISRAEL

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian A. Jonas

Research Interests

Explore related searches

Contact this professor

Articles (11)

Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Collaborators (3)

Daniel A. Pollyea

Jan Novak

Yishai Ofran

Make your next move.